Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews

A Sephien, M Ghobrial, T Reljic, X Prida… - International Journal of …, 2023 - Elsevier
Aims Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to have benefit
in patients with heart failure (HF). Multiple systematic reviews and meta-analyses (SRs and …
被引用次数：1 相关文章

EFFICACY OF SGLT2 INHIBITORS IN PATIENTS WITH HEART FAILURE: AN OVERVIEW OF SYSTEMATIC REVIEWS

A Sephien, M Ghobrial, T Reljic, XE Prida… - Journal of the American …, 2023 - jacc.org
Background Sodium-Glucose transporter 2 inhibitors (SGLT2i) have been shown to have
benefit in patients with heart failure (HF). Multiple systematic reviews and meta-analyses …

Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews.

A Sephien, M Ghobrial, T Reljic, X Prida… - … Journal of Cardiology, 2022 - europepmc.org
Aims Sodium-Glucose transporter 2 inhibitors (SGLT2i) have been shown to have benefit in
patients with heart failure (HF). Multiple systematic reviews and meta-analyses (SR and MA) …

Efficacy of SGLT2 Inhibitors in Patients with Heart Failure: An Overview of Systematic Reviews

A Sephien, M Ghobrial, T Reljic, X Prida… - 2022 - scholarlycommons.hcahealthcare …
AIMS: Sodium-Glucose transporter 2 inhibitors (SGLT2i) have been shown to have benefit in
patients with heart failure (HF). Multiple systematic reviews and meta-analyses (SR and MA) …

Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews

A Sephien, M Ghobrial, T Reljic… - International …, 2023 - internationaljournalofcardiology.com
Aims Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to have benefit
in patients with heart failure (HF). Multiple systematic reviews and meta-analyses (SRs and …

Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews

A Sephien, M Ghobrial, T Reljic… - International …, 2023 - pubmed.ncbi.nlm.nih.gov
Aims Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to have benefit
in patients with heart failure (HF). Multiple systematic reviews and meta-analyses (SRs and …